Abstract: It is provided a liquid preparation stably including (2S)-1-(4-amino-2,3,5-trimethylphenoxy)-3-{4-[4-(4-fluorobenzyl)phenyl]-1-piperazinyl}-2-propanol or its pharmaceutically acceptable salt as an active ingredient. The present invention relates to a liquid preparation including the above compound or its pharmaceutically acceptable salt as an active ingredient, the liquid preparation including: (a) at least one selected from the group consisting of sulfite, bisulfite, pyrosulfite, ?-thioglycerol and cysteine, (b) a ?-cyclodextrin derivative, and (c) a pH buffer, wherein the pH value thereof is adjusted within a range of from 3 to 5.

Abstract: A medical component comprising a human parathyroid hormone peptide or its derivative, and acetic acid contained at a concentration less than its chemical equivalent with respect to the human parathyroid hormone peptide or to its derivative. Since in the medical component acetic acid, which is present as a salt of or attached to the peptide or its derivative, has been reduced to an amount less than chemical equivalent with respect to the human parathyroid hormone peptide or its derivative, a medical component, which is highly stable and will ensure an excellent use feeling when introduced into a pharmaceutical composition, is obtained.

Abstract: A medical component comprising a human parathyroid hormone peptide or its derivative, and acetic acid contained at a concentration less than its chemical equivalent with respect to the human parathyroid hormone peptide or to its derivative. Since in the medical component acetic acid, which is present as a salt of or attached to the peptide or its derivative, has been reduced to an amount less than chemical equivalent with respect to the human parathyroid hormone peptide or its derivative, a medical component, which is highly stable and will ensure an excellent use feeling when introduced into a pharmaceutical composition, is obtained.